Intravenous Semelil (ANGIPARSâ�¢) as a novel therapy for pressure ulcers: A randomized clinical trial by Shamimi Nouri, K. et al.
 




Intravenous Semelil (ANGIPARS™) as a novel therapy for pressure 
Ulcers:  A randomized clinical trial 
 
1Shamimi Nouri K, 2,3Heshmat R, 1Karimian R, 2Nasli E, 2Larijani B, 4Novitsky YA, 
5Farhadi M, 6٭Gharibdoust F  
 
1General Surgery Department, Vali-e-Asr Hospital, Imam Khomeini Hospital Complex,  
2Endocrinology and Metabolism Research Center (EMRC), 3Department of Epidemiology and 
Biostatistics, Public Health School, Tehran University of  Medical Sciences, Tehran, Iran, 
4European-Asian Nano-molecular Technology Center, Moscow, Russia, 5ENT - Head & Neck 
Surgery Department and Research Center, Iran University of Medical Sciences, Tehran, 
6Rheumatology Research Center, Tehran University of  Medical Sciences, Tehran, Iran. 
 
ABSTRACT 
The prevalence of pressure ulcers of the foot is a major health care problem in frail elderly 
patients. A pressure sore dramatically increases the cost of medical and nursing care, and 
effective treatment has always been an essential nursing concern. Management options for 
pressure ulcers include local wound care; surgical repair and, more recently, topical 
application of growth factors. 
The main goal of this study was to examine the effects of intravenous treatment of Semelil 
(ANGIPARS™), a new herbal extract in patients with severe, noninfected pressure ulcers 
of the foot. 
As a randomized clinical trial, 18 patients with pressure ulcers were recruited from Vali-e-
Asr hospital, Medical Sciences/ University of Tehran, Iran. Nine patients received 
intravenous Semelil (ANGIPARS™) besides to conventional therapy and nine received 
only conventional treatment. 
At the baseline, the treatment and control groups did not differ across demographic 
variables, clinical characteristics, and functional measures. The mean surface areas of the 
ulcers were reduced 43.2 ± 57.4 cm2 (80.3%) and 2.8± 6.2 cm² (6.3%) in the treatment and 
control groups, respectively (p=0.000).  
The average reduction in pressure ulcer area at four weeks was statistically and clinically 
greater in the treatment group than in the control group So, intravenous Semelil 
(ANGIPARS™) can be recommended as an effective treatment for patients with severe 
pressure ulcers.  
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INTRODUCTION 
Pressure ulcers are one of the major causes of 
morbidity in older people and the most important 
care problem in nursing home residents (1,2) and 
they dramatically increase the cost of medical and 
nursing care (3). In particular, pressure ulcers of 
the foot are very common and are difficult to heal 
among elderly immobilized patients. Pressure 
ulcers at the malleolus, heel, or both develop as a 
result of pressure, shear, or friction concentrated 
on a small area over a bone prominence that lacks 
subcutaneous tissue. One of the most important 
parts in estimation of disease load is the disability 
resulting from the diseases such as injuries due to 
trauma, car accidents, brain vessel diseases, 
diabetes and osteoporosis. Induced bedsore in the 
above mentioned diseases and other reasons 
causes major problems and disabilities. 
In Iran, 5000 patients suffer from spinal cord 
injury (SCI): of these, 2000 are Iran-Iraq war 
victims and 3000 are handicapped due to other 
reason (4). In view of the enormous prevalence of 
pressure ulcers in war victims and other spinal 
handicap patients, and the importance of these 
lesions in terms of morbidity, mortality and cost 
of treatment, regardless of stage, prompt treatment 
is essential. An untreated pressure sore may 
worsen and leads to cellulites, chronic infection, 
or osteomyelitis. Management options for 
pressure ulcers include local wound care; surgical 
repair; and more recently, topical application of 
growth factors (5-6). 
Semelil (ANGIPARS™) is a new herbal extract 
which have been shown to play an important role 
in wound healing in previous clinical studies (7). 
Other basic and toxicology studies showed that 
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ANGIPARS™ has no severe acute or chronic 
toxicity (8-10) and this herbal extract in 
intravenous rout is more effective than standard 
therapy without any side effects in diabetic foot 
ulcers (11-13). 
In the present study the efficacy of intravenous 
ANGIPARS™ compared with conventional 
treatment in patients with pressure ulcers. 
 
MATERIALS AND METHODS 
A randomized controlled trial with four weeks 
follow-up was performed for patients admitted to 
Vali-e-Asr hospital, Medical Sciences/ University 
of Tehran, over a period of one year (August 2006 
and August 2007). 
All patients with ulcers resulted from spinal 
inconveniences (accidental or congenital), 
amputation of the lower limbs, chronic diseases 
like brain vessel disorders and fractures due to 
osteoporosis were included in the study. The ulcer 
size was at least 1 cm2 (measure of the longest 
length in longest width) occurring within the last 
2 weeks. All patients with acute infection of ulcer 
or any ulcer with bone exposure were excluded. 
Other exclusion criteria were: any other disease or 
situation that impairs ulcer improvement (such as 
malignancies, vasculitis, diabetes, connective 
tissue diseases, Immunity system disorders, etc.) 
alcohol and substance abuse, dialysis and renal 
failure, corticosteroid consumption, immune 
suppressive agents, radiotherapy, chemotherapy 
and any known drug hypersensitivity. 
All patients provided written informed consent at 
enrollment for pre randomization activities and at 
the initiation of treatment for follow-up activities 
and treatment. 
 
Study Design and Treatment Protocols 
After patient involvement, primary assessment in 
addition to evaluation for inclusion and exclusion 
criteria was performed as followings: 
Exact inspection of the ulcer, measurement of its 
diameters and complete explanation of the ulcer 
features; photography, mapping and planimetry. 
Patients received drugs daily and were evaluated: 
Daily wound examination before drug 
administration and renewing the dressing by a 
physician, Physical examination and taking 
history from patients, Wound debridement 
between therapies according to physicians' 
diagnosis, photography and measurement of the 
ulcer diameters to assess any improvement, 
steadiness or regression per two weeks, weekly 
documentation of patients' compliance, their 
adherence and side effects recorded and managed. 
Laboratory assessments were carried out before 
and at the end of treatment period for serum 
hemoglobin level, blood count, and serum glucose 
level. 
Nine patients received intravenous Semelil 
(ANGIPARS™) and conventional treatment, and 
nine received only conventional treatment. 
For both groups, treatment began in the absence 
of clinical signs and symptoms of active topical 
infection. All patients received the same daily 
local care. Treatment was continued either until 
the wound healed completely or for a maximum 
of four weeks.  
 
Treatment Group 
In this group each patient received four mL of 
ANGIPARS™ that was diluted in 100 mL of 
balanced salt solution, and infused for 30 minutes 
every other day for four weeks (28 days). 
 
Control Group 
In this group, a balanced salt solution was used as 






Eighteen patients were enrolled in the study and 
no clinically important differences were observed 
in their demographic or baseline characteristics 
(Table 1). They had skin ulceration for a mean of 
two months, without substantial differences 
between the treatment and control groups. 
Location of the ulcer was similar between groups. 
All of the patients continued treatment until 
completion of the trial and none of them 
experienced severe adverse consequence related 
to the treatment.   
 
Efficacy data  
Efficacy was determined by using target ulcer 
surface area measurements relative to baseline 
values taken at the start of the trial. The mean 
relative surface areas were tested for significance 
during the study period.  
Ulcer surface area in intervention group was 57.2 
± 76.7 at the first visit and after completion of the 
trial decreased to 20.0 ± 14.1 (p=0.008). In 
contrast, ulcer surface area in control group was 
19.5 ± 16.1 at the first visit and after completion 
of the trial decreased to 16.7 ± 13.6 (p=0.144). 
The mean percentages of surface reduction 
compared to the baseline size among intervention 
and control groups were: 80.3 ± 10.4 vs. 6.3 ± 
22.7, respectively (p=0.000).  
All of the ulcers were treated with intravenous 
Semelil (ANGIPARS™) showed a statistically 
significant acceleration of the healing process 
(Table 2) Advancement of epithelial tissue from 
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Table 1. Baseline characteristics of study subjects (mean ± SD) 
 ANGIPARS™ (n=9) Control  (n=9) P- value 
Age (year) 46 ± 20.6 46.0 ± 22.7 0.982 
Sex (M/F) 7/2 7/2 1.000 
Area of ulcer (cm2) 57.2 ± 76.7 19.5 ± 16.1 0.446 
Number of ulcer 1.3 ± 0.5 1.2 ± 0.7 0.882 
 
 
Table 2. Ulcer healing status among Semelil (ANGIPARS™) and control groups 
 ANGIPARS™  (n=9) Control (n=9) P- value 
Decrease in ulcer area (cm2)0.000 6.2 ± 2.8 57.4 ± 43.2 ٭ 
Decrease rate (%) 80.3 ± 10.4 6.3 ± 22.7 0.000 
Healing† > 80% 4 (44.4) 0 
 50-80% 5 (55.6) 1 (11.1) 
 20-50% 0 0 
 < 20% 0 8 (88.9) 
0.0001 
 (%) Mean ± SD; † Number٭
 
the margin toward the center of the ulcer was 
visible in all patients in the intervention group and 
the total area was reduced in all ulcers in the 
intervention group. Moreover, after Semelil 
(ANGIPARS™) intervention, the lesions in the 
intervention group showed a marked peripheral 
scar suggestive of a prompt recovery process. 
Rate of healing in the intervention group was not 
related to ulcer severity, patient age, or ulcer 
location. 
The ulcers in the control group, which were 
treated only with conventional therapy, healed 
more slowly. It is important to note that none of 
the patients experienced systemic or local side 
effects during treatment with Semelil 
(ANGIPARS™) or conventional therapy. 
 
DISCUSSION 
Pressure ulcers have been associated with 
increased mortality rates in both acute and long-
term care settings. Death has been reported to 
occur during acute hospitalization in 67% of 
patients who develop a pressure ulcer compared 
with 15% of at-risk patients without pressure 
ulcers. Patients who develop a new pressure ulcer 
within 6 weeks after hospitalization likely to die 
three times higher than patients who do not 
develop a pressure ulcer (14-15). 
In long-term care settings, development of a 
pressure ulcer within 3 months among newly 
admitted patients has been associated with a 92% 
mortality rate, compared with a mortality rate of 
4% among residents who did not subsequently 
develop a pressure ulcer (16). 
Although no gold standard for prevention or 
treatment of pressure ulcers has been established, 
data from clinical trials indicate that specific 
efforts are worthwhile. Preventive strategies 
include recognizing risk, decreasing the effects of 
pressure, assessing nutritional status, avoiding 
excessive bed rest, and preserving the integrity of 
the skin. Treatment principles include assessing 
the severity of the wound; reducing pressure, 
friction, and shear forces; optimizing wound care; 
removing necrotic debris; managing bacterial 
contamination; and correcting nutritional deficits 
(17). 
Growth factors including transforming growth 
factors alpha and beta, epidermal growth factor, 
platelet derived growth factor, fibroblast growth 
factor, interleukin-1, interleukin-2, and tumor 
necrosis factor alpha given topically have been 
demonstrated to mediate the healing process. The 
concept of acceleration of healing of chronic 
wounds by using these acute wound factors is 
attractive. However, in trials in pressure ulcers, 
platelet derived growth factor failed to produce 
complete healing (18), although it did shorten the 
time of closure of wounds, as did basic fibroblast 
growth factor (19,20). The development of wound 
healing factors is still in its infancy but shows 
great promise. 
The healing process is characterized by an 
intricate organization of cellular and molecular 
interactions. Inflammation and coagulation are 
essential preliminary processes and are followed 
by angiogenesis, cell replication, and 
epithelialization (21). The complex series of 
events resulting in the repair of coetaneous 
wounds is modulated at least in part by several 
polypeptide growth promoters, such as 
interleukins (interleukin-1, interleukin-6, and 
interleukin-8), insulin-like growth factor, 
fibroblast growth factor, epidermal growth factor, 
platelet-derived growth factor, and nerve growth 
factor (21–25). Topical treatment of wounds with 
Semelil (ANGIPARS™) has been studied in 
human models (26). However, their effectiveness 
and clinical usefulness are still doubtful. The 
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results of our randomized, controlled trial indicate 
that intravenous administration of Semelil 
(ANGIPARS™) and conventional treatment is 
more effective than only conventional therapy for 
patients with severe pressure ulcers. The first sign 
of wound healing in the treatment group was 
evident during the second week of treatment and 
was characterized by the advancement of 
epithelial tissue from the margin toward the center 
of the ulcer.  
The mechanisms responsible for the efficacy of 
this herbal extract treatment might be related to 
stimulation of proliferation of endothelial cell and 
 
vascular neoangiogenesis. 
This herbal extract may act indirectly by 
modulation of inflammation and also acts directly 
on endothelial cells and probably plays an 
important role in angiogenic activity.  
The results of this randomized, controlled trial 
indicate that intravenous application of this herbal 
extract may be an effective therapy for patients 
with severe, acute pressure ulcers. However, 
further studies are warranted for better 
understanding of the benefit of intravenous 
Semelil (ANGIPARS™) treatment in patients 
with chronic skin ulcers.  
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